Journal article
Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study
A Sharma, S Wood, JS Bell, MJ De Blasio, J Ilomäki, RH Ritchie
Lancet Regional Health Western Pacific | ELSEVIER | Published : 2023
Open access
Abstract
Background: Sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D). Despite known sex differences in diabetes-induced cardiovascular disease (CVD), pharmacological treatment recommendations are independent of sex. Our objective was to investigate possible sex differences in rates of MACE with SGLT2i vs. GLP-1RA use. Methods: This population-based cohort study included men and women with T2D (≥30 years), discharged from a Victorian hospital between 1st July 2013 and 1st July 2017, and dispensed an SGLT2i or GLP-1RA within 60 days of discharge. Using Cox ..
View full abstractGrants
Funding Acknowledgements
This work was supported in part by the Dementia Australia Yulgilbar Innovation Award. AS is supported by an Australian Government Research Training Program scholarship. The authors would also like to acknowledge the Victorian Department of Health as the source for the VAED, and the Australian Institute of Health and Welfare for provision of data linkage.